Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) determinants in Tuberous Sclerosis Complex (TSC)

We are currently conducting a clinical research study at Boston Children’s Hospital for individuals between the ages of 3-21 years with a diagnosis of tuberous sclerosis complex (TSC) and autism spectrum disorder (ASD) and/or intellectual disability (ID). The goal of this study is to gain a better understanding of ASD/ID in individuals with TSC so that effective treatments and interventions for ASD/ID can be found. This is a multi-center research study conducted as part of the Rare Disease Clinical Research Network (RDCRN) and sponsored by the National Institutes of Health (NIH). Follow this link for more information about this Consortium. 

English speaking individuals diagnosed with TSC and autism spectrum disorder and/or intellectual disability are eligible to participate in this study if they are between the ages of 3 and 21 years old.

The study involves five visits over a two year period. Three of the visits occur on site at the study location and involve a blood draw, physical and neurological exam and developmental testing. Two visits occur as phone calls and involve answering questionnaires about behavior and development.

If you are interested in participating in this research study please contact Erin Carmody at 617-919-4599 or erin.carmody@childrens.harvard.edu.


Preventing Epilpesy Using Vigabatrin in Infants with Tuberous Sclerosis Complex (PREVeNT Trial) - click the link for more information